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ABSTRACT
Animal models reflective of ulcerative colitis (UC) remain a major
challenge, and yet are crucial to understand mechanisms underlying
the onset of disease and inflammatory characteristics of relapses and
remission. Mouse models in which colitis-like symptoms are induced
through challenge with toxins such as oxazolone, dextran sodium
sulfate (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) have been
instrumental in understanding the inflammatory processes of UC.
However, these neither reflect the heterogeneous symptoms observed
in theUC-affected populationnorcan they beused to test the efficacyof
inhibitors developed against human targets where high sequence and
structural similarity of the respective ligands is lacking. In an attempt
to overcome these problems, we have developed a mouse model
that relies on NOD-scid IL2R γnull mice reconstituted with peripheral
blood mononuclear cells derived from UC-affected individuals.
Upon challenge with ethanol, mice developed colitis-like symptoms
and changes in the colon architecture, characterized by influx of
inflammatory cells, edema, crypt loss, crypt abscesses and epithelial
hyperplasia, as previously observed in immune-competent mice.
TARC, TGFβ1 and HGF expression increased in distal parts of the
colon. Analysis of human leucocytes isolated from mouse spleen
revealed an increase in frequencies of CD1a+, CD64+, CD163+ and
TSLPR+ CD14+ monocytes, and antigen-experienced CD44+ CD4+
andCD8+T-cells in response toethanol. Analysis of human leucocytes
from the colon of challenged mice identified CD14+ monocytes and
CD11b+monocytes as the predominant populations. Quantitative real-
time PCR (RT-PCR) analysis from distal parts of the colon indicated
that IFNγmight be one of the cytokines driving inflammation. Treatment
with infliximab ameliorated symptoms and pathological manifestations,
whereas pitrakinra had no therapeutic benefit. Thus, this model is
partially reflective of the human disease and might help to increase the
translation of animal and clinical studies.
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INTRODUCTION
Animal models present one of the biggest scientific challenges
in exploring the etiology of complex inflammatory diseases.
For practical reasons, mice are the preferred animals in which
cases of ulcerative colitis (UC) are usually induced with toxins
such as oxazolone, dextran sodium sulphate (DSS) or 2,4,6-
trinitrobenzenesulfonic acid (TNBS), leading to the development of
colitis-like symptoms (Kiesler et al., 2015). However, these models
differ substantially from the human disease because they poorly
reflect the pathophysiological mechanisms of a genetically
heterogeneous population of affected individuals that are often
diseased for decades. In addition, they cannot be used when species-
specific responses are involved, or when high sequence and/or
structural similarity between inhibitors and ligands across species is
required in order to interact with receptors of interest. Therefore, we
have developed a model that is based on immunocompromised
NOD-scid IL2R γnull (NSG) mice reconstituted with peripheral
blood mononuclear cells (PBMCs) derived from UC-affected
individuals (Nolte et al., 2013a). In this model, UC-like
symptoms were induced through rectal challenge with oxazolone.
Unexpectedly, similar, albeit milder, effects were observed with
ethanol as the solvent for oxazolonewhen a UC individual served as
donor. This observation prompted us to assume that the
inflammatory cells of UC individuals increase the susceptibility
of mice to develop colitis and thus might be more reflective of the
human disease. Here, we report that NSG mice reconstituted with
PBMCs derived from UC individuals developed similar symptoms
to those previously observed in oxazolone-challenged mice (Nolte
et al., 2013a). Challenge with ethanol resulted in a mixed infiltrate
of immune cells into the lamina propria that comprised CD4+,
CD8+ T-cells, CD11b+ macrophages and CD14+ monocytes.
Colon architecture was characterized by the development of edema,
fibrosis, crypt abscesses and hemorrhage. The severity of
disease symptoms and pathological manifestations were donor
dependent. The response to ethanol resulted in an increase of
subtypes of CD14+monocytes to include CD64-, CD163-, TSLPR-
and CD1a-expressing monocytes, as well as antigen-experienced
CD4+ splenic human leucocytes. Treatment with infliximab
ameliorated the symptoms and pathological manifestations,
and resulted in a similar immunological signature to that observed
in UC individuals treated with infliximab (Ulrich Mansmann and
our unpublished data), characterized by increased levels of fibrosis,
and reduced HGF and TARC expression. Conversely, treatment
with the IL-4Rα inhibitor pitrakinra had no therapeutic effect but
exacerbated symptoms and pathological manifestations. Treatment
resulted in an increase of CD8+ cells and central memoryReceived 17 March 2016; Accepted 19 July 2016
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CD8+ cells in splenic human leucocytes and decreased fibrosis,
suggesting that the suppression of the T-helper cell 2 (Th2)
inflammatory arm favors an auto-immune reaction to increase
damage to the mucosa.
RESULTS
Characterization of inflammatory response in ethanol-
challenged mice
In order to gain a better understanding of the inflammatory
responses evoked by the challenge with ethanol in NSG mice
reconstituted with PBMCs derived from UC-affected individuals
and to elucidate whether this model is reflective of the human
disease, the response to challenge was analyzed with regard to the
development of a clinical and histological score, macroscopic
changes of the colon, the frequency of leucocytes isolated from the
spleen and colon, and cytokine and growth factor expression in the
colon. Mice were reconstituted with 3×106-4×106 human PBMCs
from UC individuals (n=5) as described in Materials and Methods.
All donors had clinical activity scores between 5 and 10, as
determined by the simple clinical colitis activity indices (SCCAI),
and were considered as being in relapse. Two donors were treated
with infliximab, one with mesalazine and two were untreated. To
determine the profile of cells that had been injected into the mice,
PBMCs were subjected to flow cytometric analysis before injection.
As shown in Fig. 1, all donors exhibited high levels of antigen-
experienced CD4+ T-cells, CD14+ monocytes and CD11b+
macrophages as compared to non-UC subjects. This also applied
to effector memory CD8+ T-cells, with the exception of donor
3. Donor 3 also differed from the other donors with regard to CD1a+
monocytes, where all other donors displayed elevated levels as
compared to non-UC subjects. The highest variability between
donors was observed in CD1a-expressing CD11b+ macrophages.
Seven days post reconstitution, the mice were divided into two
groups: one was left unchallenged and the other was challenged
through rectal application of ethanol. Each group contained four
animals. As we had previously observed high toxicity of oxazolone
in non-reconstituted mice, an additional control comprising non-
reconstituted mice was added (Nolte et al., 2013a). In addition, to
support our previous observations that the histological score was
highest when PBMCs from a donor with UC was used for
reconstitution, a group of mice was added that had been
reconstituted with PBMCs from a non-UC donor. On day seven,
mice were pre-sensitized with rectal application of 10% ethanol,
followed by rectal application of 50% ethanol at days 15 and 18. The
onset of the disease was monitored by measuring body weight, and
visual inspection of stools and mice. Symptoms were classified
according to a clinical activity score as described in Materials and
Methods. Upon challenge with ethanol, stools of mice reconstituted
with PBMCs fromUC donors became soft or liquid, the animals lost
weight and the activity was reduced. Unchallenged control
animals displayed no symptoms. Symptoms peaked at day 16,
and challenged animals recovered two days post challenge. All
animals except one survived. The development of symptoms was
reflected in the clinical activity score of the challenged group, which
was significantly higher as compared to that of the unchallenged
group (Fig. 2A). (For complete data set see Table S1.) As observed
in previous experiments, unchallenged control animals remained
unaffected. We observed a high variability between different
donors. Mice reconstituted with a non-UC donor also developed a
higher clinical score, but unlike the group that had been
reconstituted with PBMCs from UC donors, the stool consistency
was unaffected. As previously observed in oxazolone-challenged
mice, challenge with ethanol in the absence of PBMCs was highly
toxic, and three animals had to be euthanatized before the end of the
study. These animals also displayed no diarrhea.
On day 21, mice were killed, the colon was visually inspected,
and colon samples from the distal part of the colon were collected
for histological and mRNA expression analysis, and leucocytes
were isolated from spleen and colon. Visual inspection of the colon
corroborated the observed clinical scores.
As shown in Fig. 2B, challenge with ethanol affected mice
differently, dependent on the presence of PBMCs and the
immunological background of the donor. When mice that had been
reconstituted with PBMCs from a UC donor were challenged with
ethanol, the colon had been emptied of stool and was dilated, and in
some cases, displayed hyperemia (Fig. 2Bb). In contrast, colons of
control animals displayed no signs of diarrhea or inflammation as
indicated by solid and evenly dispersed stool pellets (Fig. 2Ba).
Colons of mice reconstituted with PBMCs from a healthy donor
displayed no signs of inflammation and were indistinguishable from
colons of the control group of unchallenged mice (Fig. 2Bc). In
contrast, in the absence of PBMCs, challenge with ethanol resulted in
severe damage of the colon (Fig. 2Bd). Exactly in the region where
the concentration of ethanol was supposedly high, the colon was
constipated, indicating loss of peristaltic movement. The same
observations were made in a previous study (Nolte et al., 2013a) in
which oxazolonewas used to induce colitis; however, in that case, the
toxicity of oxazolone was even higher. Histological analysis further
corroborated these observations. Analysis of hematoxylin and eosin
(H&E)-stained sections from the distal part of the colon of mice that
had been reconstituted with PBMCs from a UC donor revealed that
the response to challenge with ethanol resulted in morphological
changes of the colon architecture that were characterized by edema,
influx of a mixed infiltrate of leucocytes into the mucosa and
submucosa, focal fibrosis of the mucosa, epithelial erosions, single
crypt abscesses and hyperemia. In addition, increased basophilia at
the base of the crypts indicated epithelial proliferation (Fig. 3Ab).
Hardly any morphological changes were observed when mice were
reconstituted with PBMCs from a healthy donor (Fig. 3Ac).
In the absence of PBMCs, challenge with ethanol resulted in
severe damage of the mucosa, similar to that observed in mice
challenged with oxazolone. Mucosal damage was accompanied by
strong influx of neutrophils (Fig. 3Ad).
The morphological changes were classified according to a
histological score as described in Materials and Methods. As
observed with the clinical activity score, the degree of pathological
manifestation varied between experiments and indicated a donor-
to-donor variability. As shown in Fig. 3B, the histological score
in all challenged groups was significantly higher as compared to
the control groups (for complete data set see Table S1). The
histological score was lowest when mice were reconstituted with
PBMCs from a non-UC donor, and it was highest in the absence of
PBMCs. In order to examine whether impaired mucus production
could lead to toxic responses to ethanol, periodic-acid–Schiff
staining (PAS) was performed. As shown in Fig. 3C, in sections of
wild-type BALB/c mice, the number of PAS-stained cells was
higher, and the distribution of goblet cells more regular as
compared to NSG mice.
To further characterize the inflammatory response, human
leucocytes that had been isolated from murine spleens were
subjected to flow cytometric analysis according to the cellular
markers displayed in Table S5 (for gating strategy see Fig. S1).
Human leucocytes that had been isolated from the spleen of mice
reconstituted with PBMCs from a non-UC individual and a UC
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Fig. 1. The immunological profile of donor PMBCs selected to reconstitute mice. Boxplot analysis of isolated PBMCs that were subjected to flow cytometric
analysis. Sample size: CD4+, CD4+ CD44+ CD62L−, CD8+, CD8+ CD44+ CD62L−, CD14+ non-UC n=30, UC n=40; CD11b+, CD11b+ CD1a+ non-UC n=31,
UC n=40; CD11b+ TSLPR+, CD14+ TSLPR+ non-UC n=15, UC n=40; CD14+ CD1a+ non-UC n=9, UC n=27. Labels given on x-axes on the bottom row
apply to all charts. Boxes represent upper and lower quartiles, whiskers represent variability and outliers are plotted as individual points. Lines represent values
without variability. D, donor.
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individual displayed different patterns in response to ethanol
(Fig. 4). Frequencies of human leucocytes isolated from the
spleen of mice that had been reconstituted with PBMCs from
the non-UC donor did not change in response to ethanol, with the
exception of antigen-experienced CD4+ T-cells. In addition,
experienced CD8+ T-cells were not detected. In contrast, ethanol
induced a change in frequencies of human leucocytes. Analysis of
human CD45 revealed mean engraftment levels of 9.07%±9.25
leucocytes (mean±s.d.) in the control group and 15.46%±12.69 in
the challenged group (for complete data set see Table S1). The
increase just failed to reach significance (P=0.07). Challenge with
ethanol resulted in a significant increase in antigen-experienced
CD4+ T-cells, and subsets of CD14+ monocytes such as CD64+,
CD163+, CCR4+, CD1a+ monocytes. TSLPR-expressing
monocytes displayed a trend towards significance. In contrast, a
significant decline in effector memory CD8+ cells was observed
(for complete data set, please see Table S1). As observed in the
clinical and histological scores, variability was high.
Previous analysis has identified human T-cells as infiltrating cells
when oxazolone is used as toxic agent (Nolte et al., 2013a). In order
to further analyze the infiltrating cells, human leucocytes were
isolated from mice colons and subjected to flow cytometric analysis
as described in Materials and Methods (for gating strategy see
Fig. S2). Owing to the low frequency of leucocytes, colons from
each group were pooled for this experiment. As shown in Fig. 5A,
CD14+ monocytes and CD11b+ macrophages were the most
abundant populations and exceeded CD4+ and CD8+ T-cells in
number. The variability of frequencies was high and reflected
the donor-to-donor variability. The most abundant subsets of
monocytes and macrophages were those that expressed CD1a or
TSLPR. In addition, mRNA expression of mouse TGFβ1, HGF and
mouse TARC increased significantly upon ethanol challenge, as
observed in UC individuals.
Response to treatment with infliximab and pitrakinra
Inhibitors are valuable tools to characterize inflammatory responses
in a complex setting that involves the cross-talk of various cell types.
One of the most efficacious therapeutic for UC is the anti-TNFα
monoclonal antibody infliximab, although initially it had not been
considered as a therapeutic for UC. In contrast to Crohn’s disease,
inflammation in UC has not been thought to be driven by TNFα.
Therefore, it is still a point of discussion how infliximab exerts its
efficacy. As the IgG1 effector function of the antibody seems
crucial, it has now been suggested that binding of infliximab to
surface TNFα might activate complement and induce apoptosis in
TNFα-bearing cells (Scallon et al., 1995). In light of this, it seemed
an attractive idea to examine the efficacy of infliximab at a cellular
level in our mouse model. NSG mice were reconstituted as
described above in the previous experiment, this time, however, a
third group was added, which was treated with intraperitoneal
injection of infliximab on days 7, 14 and 17. The isotype
monoclonal antibody served as an additional control. The
experiment was performed with two different donors, and each
group contained four animals. All mice were subjected to the same
analysis as in the previous experiment.
As shown in Fig. 6, mice responded to treatment with infliximab
(for complete data set see Table S2). Visual inspections of
histological sections from distal parts of the colon revealed an
influx of inflammatory cells into the lamina propria, however, at a
reduced level (Fig. 6A) as compared to that in the ethanol-challenged
group (Fig. 3Ab-Ah). Ethanol-induced fibrosis did not seem to be
affected by infliximab. The clinical activity score almost returned to
normal values, and this was reflected in the histological score
(Fig. 6B). Treatment with infliximab affected human leucocytes that
had been isolated from the spleen. Frequencies of antigen-
experienced CD4+ T-cells and CD1a+ CD11b+ macrophages, as
well as of CD64+ and CD1a+ CD14+ monocytes, increased in
response to ethanol and declined when mice were treated with
infliximab (Fig. 6C). Finally, mouse TGFβ1 expression was
unaffected in contrast to that of HGF and mouse TARC (Fig. 6D).
This result is consistent with data obtained from UC individuals.
Here, treatment with blockers of TNFα resulted in increased
expression of TGFβ1 whereas HGF and TARC expression levels
decreased (Ulrich Mansmann and our unpublished data). In mice
reconstituted with PBMCs from donor 5, human IFNγ was detected.
The level increased in response to challenge with ethanol and
decreased when mice were treated with infliximab.
IL-4 and IL-13 are thought to play a crucial role in Th2-
characterized inflammatory diseases such as asthma and atopic
dermatitis. Both exert their activities on the IL-4 receptor α1
Fig. 2. Challenge with ethanol results in development of colitis-like symptoms in NSG mice that had been engrafted with PMBCs derived from a UC
individual. (A) Clinical activity score depicted as a boxplot diagram. Sample sizes: mice reconstituted with PBMCs from a non-UC donor, unchallenged control,
n=4; challenged (ethanol) control, n=4. Mice reconstituted with PBMCs from a UC donor, unchallenged control, n=20; challenged, n=20. Non-reconstituted
mice (no PMBC), unchallenged, n=4; challenged, n=4. For comparison of unchallenged control versus challenged, a Student’s t-test was performed. Boxes
represent upper and lower quartiles, whiskers represent variability and outliers are plotted as individual points. Lines represent values without variability.
(B) Macrophotographs of colons at autopsy of NSG mice that had been engrafted with PBMCs from a UC donor. (a) unchallenged control, (b) challenged with
ethanol, (c) engrafted with PBMCs from a non-UC donor challenged with ethanol, (d) non-engrafted challenged with ethanol. Scale bar: 10 cm.
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(IL-4Rα1), which can either form a ternary complex type I with IL
receptor common chain γ in the case of IL-4 or ternary complex type
II with the IL-13α1 receptor in the case of IL-4 and IL-13.
Activation of the type I complex leads to differentiation and
proliferation of Th2 cells, as well as activation of the type II complex
resulting in pathological manifestations such as fibrosis, mucus
production and epithelial hyperplasia, and IgM-to-IgE switch
(Mueller et al., 2002; LaPorte et al., 2008). As these pathological
manifestations are hallmarks of asthma and atopic dermatitis,
IL-4Rα1 has become a therapeutic target, and inhibition of IL-4Rα1
by the IL-4 variant pitrakinra or inhibitory monoclonal antibody
dupilumab has shown efficacy in phase II clinical studies in asthma
and atopic dermatitis, respectively (Wenzel et al., 2007; Beck et al.,
2014). Because UC is also thought to be a Th2-characterized
inflammation, albeit less clearly defined than in the two other
diseases, we thought it an attractive idea to use pitrakinra in order to
test for a potential therapeutic benefit. The target cells of pitrakinra
in the mouse model are human leucocytes bearing the IL-4 receptor.
This applies to subtypes of T-cells such as Th2 cells and subtypes
of monocytes that have developed into M2 macrophages in the
presence of IL-4 (Orme and Mohan, 2012). The experiment was
conducted as the previous experiment above; however, in this
experiment, mice were treated through intraperitoneal application
of pitrakinra on days 7-9 and 14-21, as described in Materials and
Methods. The experiment was performed with three different
donors. Isotonic NaCl solution served as an additional control in the
ethanol-challenged mice. The experiment was performed with three
different donors, and each group contained four animals.
Fig. 3. Morphological changes in response to ethanol were dependent on the immunological background of the donor and the presence of PBMCs.
Challenge of NSG mice with 10% ethanol at day 7, and 50% ethanol at days 15 and 18 that had been engrafted with PBMCs from a UC donor resulted in edema,
crypt abscesses, crypt loss, fibrosis, epithelial erosionsand infiltration of inflammatory cells into the submucosaand lamina propria. ChallengeofNSGmiceengrafted
with PBMCs from a non-UC donor had no effect, and challenge of non-engrafted NSG mice resulted in influx of neutrophils, crypt loss and edema.
(A) Photomicrographs of stained H&E paraffin sections of distal parts of the colons of NSG mice that had been engrafted with PBMCs derived from UC donors.
(a) Engrafted with PBMCs from a UC donor, unchallenged control. (b,e,f,g,h) engrafted with PBMCs from a UC donor and challenged with ethanol. Arrow indicates
influx of inflammatory cells; bold arrow, crypt abscesses; arrowhead, fibrosis. (c) Engrafted with PBMCs from a non-UC donor, challenged with ethanol.
(d) Non-engrafted, challenged with ethanol. (B) Histological alterations were classified according to a histological score and depicted as a boxplot diagram. Non-UC
sample sizes, unchallenged control, n=4; challenged with ethanol, n=4. UC: experiments were performed with five different donors. Sample sizes: unchallenged
control, n=20; challenged with ethanol, n=20. No PBMC sample sizes: unchallenged, n=1; challenged, n=4. A two-sided Student’s t-test and confidence level=0.95
was used to compare groups. Boxes represent upper and lower quartiles, whiskers represent variability and outliers are plotted as individual points. Lines represent
values without variability. (C) Photomicrographs of PAS-stained paraffin sections of distal parts of the colon. (a) BALB/c mouse; (b) non-engrafted NSG mouse.
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Unexpectedly, treatment with pitrakinra had almost opposing
effects to treatment with infliximab. Visual inspection of
histological sections from distal parts of the colon revealed a
strong influx of inflammatory cells in the lamina propria and
mesenterium. Fibrosis seemed to not be as pronounced as in
ethanol-challenged groups or as in ethanol-challenged groups
treated with infliximab Fig. 7A. As shown in Fig. 7B, no
improvement was observed with regard to the clinical activity and
histological score. (For complete data set see Table S3.) The effect
seen in human leucocytes that had been isolated from spleen of
NSG mice might give an explanation to that observation.
Frequencies of CD3+, CD8+, effector memory CD8+ and central
memory CD8+ T-cells, and CCR4+ CD11b+ macrophages and
CCR4+ CD14+ monocytes increased upon treatment with
pitrakinra, suggesting that impairment of the Th2 inflammatory
arm tipped the balance towards a T-helper cell 1 (Th1)-type
inflammation. Conversely, an inhibitory effect was observed on the
subset of monocytes that included TSLPR-, CD1a-, CD64- and
CD163-expressing CD14+ monocytes, which were considered to
be part of the ‘remodeling’ condition defined in humans with the
exception of CD64+ CD14+ monocytes. In contrast to infliximab,
TGFβ1 mRNA levels declined in response to treatment with
pitrakinra, and mouse TARC mRNA expression levels increased.
Increased TARC expression levels were found to be associated with
an acute inflammatory condition in UC individuals (Ulrich
Mansmann and our unpublished data). In addition, TARC
expression was paralleled by an increase of CD14+ monocytes
and CD11b+ macrophages bearing the TARC receptor CCR4.
Furthermore, human IFNγ was increased in the pitrakinra-treated
group, corroborating the shift towards a Th1 response. In this group,
human TNFα could also be detected.
DISCUSSION
The first aim of this study was to characterize the inflammatory
response mounted in NSG mice that had been reconstituted with
PBMCs derived from donors with UC upon challenge with ethanol.
The second aim was to examine whether this model can be used for
testing therapeutics addressing human target molecules, and the
third was to elucidate whether, and to what degree, the evoked
inflammation is reflective of the human disease.
Characterization of the inflammation
As observed in conventional UC animal models that are based on
immune-competent mice that have been exposed to toxic agents
such as oxazolone, DSS or TNBS, challenge with ethanol resulted
in weight loss, diarrhea, influx of leucocytes comprising
lymphocytes, macrophages and neutrophils into the mucosa in
NSG mice reconstituted with PBMCs from UC subjects. The
inflammatory response resulted in an altered colon architecture
characterized by edema, crypt loss, crypt abscesses, fibrosis and
epithelial hyperplasia in reconstituted NSG mice. All these
pathological manifestations were similar, albeit much less
pronounced as compared to in the DSS mouse model, for
example, and confirmed some of the previous results (Nolte et al.,
2013a). The clinical activity and histological scores were highly
donor dependent, suggesting that PBMCs from UC donors bear the
memory of previous inflammations or possess a higher capacity to
respond to challenge. This observation is also in agreement with
previous data obtained in similar models (Nolte et al., 2013b;
Zadeh-Khorasani et al., 2013). Analysis of human leucocytes that
had been isolated from spleens of mice revealed that application
of ethanol significantly affected antigen-experienced CD4+ and
CD8+ T-cells and subtypes of CD14+ monocytes, indicating
Fig. 4. Challenge with ethanol affected subgroups of human T-cells and CD14+ monocytes isolated from spleens of NSG mice that had been
reconstitutedwith PBMCs from aUC-affected individual. Boxplot analysis of human leucocytes isolated from spleens of mice and subjected to flow cytometry
analysis for the indicated markers. Mice were challenged with 10% ethanol at day 7, and 50% ethanol at days 15 and 18. Experiments were performed with five
different UC donors and one non-UC donor. Labels given on x-axes on the bottom row apply to all charts. (For sample sizes and complete data set see Table S1).
For comparison of control versus challenged, a Student’s t-test was performed. Boxes represent upper and lower quartiles, whiskers represent variability and
outliers are plotted as individual points. Lines represent values without variability.
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that CD14+ monocytes and T-cells are the main driver of this
inflammatory response. Frequencies of three subtypes, namely
CD64-, TSLPR- and CD1a-expressing monocytes have the capacity
to relay inflammatory signals, and all of these cell types were
increased in number upon challenge. CD64 is the FcγR1 receptor,
which binds to immune complexes comprising IgG-antigen
complexes and which can induce CD4+ and CD8+ T-cell
activation when expressed on monocyte-derived dendritic cells
(Schuurhuis et al., 2002; Tanaka et al., 2009; Uo et al., 2013). CD1a
has been known for decades as a phenotypic marker of human
epidermal Langerhans cells (LC). Like the other members of the
CD1 family, CD1a displays lipids; however, unlike the other
members, presentation to T-cells evokes the release of IL-22, IL-13
and IFNγ from T-cells. The role of CD1a macrophages and
monocytes in UC has yet to be examined as it is unclear whether this
effect is beneficial or further fuels inflammation.
Finally, TSLPR is thought to mediate signals released from
epithelial cells that secrete TSLP in response to damage, thereby
activating memory T-cells and natural killer T-cells to release
Th2-type cytokines and monocyte-derived dendritic cells to
promote a Th2 response, resulting in a healing process (Soumelis
et al., 2002; Nagata et al., 2007; Ito et al., 2012). This idea is
supported by the observed increase of HGF, TGFβ1 and TARC
expression, all of which are important factors in wound healing
processes. The fact that both CD64+ and CD1a+ monocytes have
the potential to induce autoimmune responses that cause damage to
epithelial cells and the fact that activation of CD8+ cells was
observed upon challenge with ethanol suggests that the observed
inflammation might be driven by an ‘autoimmune’ response,
meaning that the aspect of autoimmunity in UC might be examined
and addressed in this model. As one of the susceptibility loci for UC
is the gene encoding IL-10, loss of tolerance has been considered as
Fig. 5. Challenge with ethanol induces influx of inflammatory cells into the colon and increased expression of TGFβ1 and HGF in NSG mice that had
been reconstituted with PBMCs from UC donors. (A) Identification of T-cells, macrophages and monocyte populations. Human leucocytes were isolated
from colons of mice that had been challenged with ethanol and were subjected to flow cytometry analysis. Frequency of CD11b+ macrophages, CD14+
monocytes, and CD4+ and CD8+ T-cells, and the frequency of subtypes of CD11b+ macrophages and CD14+ monocytes in the colon of challenged NSGmice.
Sample size: n=6. Mean values are given, error bars are s.d. (B) Boxplot analysis of mRNA expression of mouse (m)TGFβ1, HGF and mouse (m)TARC in
distal parts of the colon of NSGmice in response to challengewith 10% ethanol at day 7, and 50% ethanol at days 15 and 18. RNAwas isolated from distal parts of
the colon and subjected to RT-PCR analysis. Sample size: unchallenged control, n=16; challenged with ethanol, n=16. For comparison of control versus
challenged, a Student’s t-test and confidence level=0.95 was used (for complete data set see Table S1). Boxes represent upper and lower quartiles, whiskers
represent variability and outliers are plotted as individual points. Lines represent values without variability. Ig - delta CT, logarithmic delta cycle threshold; parent,
parent cell population that subgroups were gated from.
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a driver of the disease for some time (McGovern et al., 2010). This
idea is also corroborated by various animal models in which either
loss of IL-10 induces spontaneous colitis or application of IL-10
ameliorates disease symptoms (Kuhn et al., 1993; Steidler et al.,
2000). However, it has been thought that commensal bacteria,
which are immunologically silent under healthy conditions, were
the preferred targets of the autoimmune response. Recently, other
autoreactive antibodies, such as perinuclear anti-neutrophil
cytoplasmic antibodies (pANCAs) and those that recognize
goblet cells and granulocyte macrophage colony-stimulating
factor have been detected in UC individuals, expanding the view
of autoimmunity in UC (Seibold et al., 1998; Kovacs et al., 2012;
Dabritz et al., 2013). Whether these autoantibodies are causative for
or are the result of ongoing inflammation, for sometimes decades,
remains to be determined.
CD14+ CD163+monocytes are sometimes considered as counter
players of CD14+ CD64+ monocytes because they play a crucial
role in resolution of inflammation. The fact that both frequencies
of both subtypes are elevated might indicate that resolution of
inflammation is an intrinsic part of the inflammatory response.
The fact that TGFβ1, TARC and HGF expression levels increase
upon challenge with ethanol strongly supports our hypothesis that
Fig. 6. The therapeutic effect of infliximab in reconstituted NSGmice challengedwith ethanol. (A) Photomicrographs of H&E-stained sections of distal parts
of the colon from mice that had been challenged with 10% ethanol at day 7, and with 50% ethanol at days 15 and 18, and treated with infliximab at days 7, 14 and
17. Arrow indicates influx of inflammatory cells, bold arrow indicates fibrosis. (B) Boxplot analysis of the clinical activity and histological score. (C) Boxplot analysis
of the frequency of human leucocytes isolated from spleen of NSG mice that had been treated as described in A. Quantification was performed using flow
cytometry. (D) Boxplot analysis of mouse (m)TGFβ1 andmHGFexpression in colon of NSGmice. RNAwas isolated from distal parts of the colon and subjected to
RT-PCR analysis. Experiments were performed with PBMCs from two different donors. Sample sizes: unchallenged control. n=8; challenged with ethanol and
treated with isotype control, n=8; challenged with ethanol and treated with infliximab, n=8. For comparison of groups, ANOVA followed by Tukey’s HSD was
conducted. Labels given on x-axes on the bottom rowapply to all charts. Boxes represent upper and lower quartiles, whiskers represent variability and outliers are
plotted as individual points. Lines represent values without variability. Ig - delta CT, logarithmic delta cycle threshold.
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Fig. 7. Pitrakinra shows no therapeutic
benefit in NSG mice challenged with
ethanol. (A) Photomicrographs of H&E-
stained sections of distal parts of the colon
from mice challenged with 10% ethanol at
day 7, and with 50% ethanol at days 15 and
18, and treated with pitrakinra on days 7-9
and 14-21. Arrow indicates edema, and
bold arrows indicate influx of inflammatory
cells into the mesenterium. (B) Boxplot
analysis of the clinical activity and
histological scores. (C) Boxplot analysis of
frequencies of the indicated human
leucocytes that had been isolated from
spleens and subjected to flow cytometry
analysis. Experiments were performed with
PBMCs from three different donors. Sample
sizes: unchallenged control, n=12;
challenged with ethanol and treated with
solvent (carrier, isotonic sodium chloride
solution), n=12; challenged with ethanol
and treated with pitrakinra, n=11. (D)
Boxplot analysis of mouse (m)TGFβ1, HGF
and mouse (m)TARC mRNA expression in
the colon of NSG mice. Human (h)TNFα
and human (h)IFNγ mRNA was also
measured. RNA was isolated from distal
parts of the colon and subjected to RT-PCR
analysis. Experiments were performed with
PBMCs from two different donors. Sample
sizes: unchallenged control, n=12;
challenged with ethanol and treated with
solvent, n=12; challenged with ethanol and
treated with pitrakinra, n=11. (For complete
data set, see Table S3.) For comparison of
groups, ANOVA followed by Tukey’s HSD
was conducted. Labels given on x-axes on
the bottom row apply to all charts. Boxes
represent upper and lower quartiles,
whiskers represent variability and outliers
are plotted as individual points. Lines
represent values without variability. Ig -
delta CT, logarithmic delta cycle threshold.
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part of the inflammatory response are wound healing processes
to protect the damaged epithelia. Increased HGF expression
corroborated the observation of epithelial proliferation in
histological sections from ethanol-challenged mice.
Although below detection level in most challenged mice, the
expression of IFNγ could be verified, especially in mice that had
been treated with pitrakinra. Suppression of wound healing
processes most probably results in increased inflammation,
reflected by the expression of human IFNγ and human TNFα.
Treatment with infliximab
Ethanol-challenged mice responded to treatment with the anti-
TNFα monoclonal antibody infliximab, which has become the
preferred therapeutic in severe cases of UC. Both, the clinical
activity and the histological score declined in mice that had been
treated with infliximab. Most probably, infliximab not only exerts
its activity by trapping soluble TNFα but also by binding to surface-
bound TNFα that is expressed by T-cells, macrophages and
monocytes, thereby inducing apoptosis through the IgG1 effector
function (Scallon et al., 1995). Analysis of human leucocytes that
had been isolated from mice treated with infliximab corroborated
this assumption. Treatment with infliximab resulted in a decline of
antigen-experienced CD4+ cells and CD14+ monocytes bearing
CD64, CD1a and CD163, all of which were increased in response to
challenge with ethanol. As observed in UC individuals, treatment
with infliximab had opposing effects on HGF, TARC and TGFβ1
expression (Ulrich Mansmann and our unpublished data).
Infliximab reduced HGF and TARC expression, and supported
TGFβ1 expression, albeit the effect on TGFβ1 expression in mice
was not as profound as that in humans.
The mechanism by which infliximab exerts its efficacy might be
explained by the two inflammatory responses prevailing in UC-
affected humans. Here, an acute response was defined by the
presence of immune cells of the adaptive immunity, CD11b+
macrophages and elevated expression of HGF and TARC.
Treatment with blockers of TNFα led to the suppression of this
acute inflammation and favored the remodeling inflammatory
condition characterized by CD14+monocytes, natural killer T-cells,
and elevated expression of TGFβ1 and periostin (Ulrich Mansmann
and our unpublished data). Although this profile was not completely
reflected in the mouse model, the data suggest an impairment of the
acute arm of inflammation by infliximab while leaving the
remodeling arm unaffected.
Treatment with pitrakinra
Rather unexpectedly, treatment with pitrakinra exacerbated the
inflammatory response. The clinical activity and the histological
score did not decline, and visual inspection of histological sections
revealed an ongoing severe inflammation. Analysis of human
leucocytes that had been isolated from spleens might give an
explanation. Treatment with pitrakinra resulted in an increase of
CD3+, CD8+ and central memory CD8+ T-cells, along with CCR4-
expressing CD11b+ macrophages and CD14+ monocytes. In
contrast, subtypes of CD14+ monocytes, which are supposed to
express IL-4Rα1, declined, and this was accompanied by decreased
expression of TGFβ1 and HGF. Conversely, TARC expression
levels were increased. These results might also be explained by the
identified inflammatory conditions in UC-affected individuals
(Ulrich Mansmann and our unpublished data). Pitrakinra might
impair the wound healing arm of inflammation that is driven by a
Th2-characterized inflammatory environment, thus favoring the
acute arm that is characterized by activated CD8+ cells. This
assumption is corroborated by previous findings that relate
fibrogenesis to IL-13 (Fichtner-Feigl et al., 2007). The futility of
addressing this arm of inflammation by suppressing Th2 responses
was also corroborated by a clinical phase II trial using
anrukinzumab. Treatment with the anti-IL-13 antibody had no
effect on the clinical score (Reinisch et al., 2015). The idea that
pitrakinra favors the acute inflammatory condition is also supported
by the increased expression of TARC and decreased expression of
TGFβ1. Both were found to be associated with acute and
remodeling inflammatory conditions in UC-affected individuals
(Ulrich Mansmann and our unpublished data).
Thus, how reflective is this model of the human disease?
Obviously, one cannot expect to cover all aspects of this complex
and highly dynamic disease. Manifestations of the disease are
extremely diverse and might have different causes, all of which are
covered by the umbrella diagnosis of UC. One also has to keep in
mind that, in this model, inflammatory responses are restricted to
PBMCs, which do not represent the entire repertoire of inflammatory
cells. However, as discussed for UC, monocytes and macrophages
play a crucial role in the mouse model, either fueling the
inflammatory response or guiding it towards wound healing
processes. In this model, cell types were detected that have been
previously identified as being crucial to pathology in UC patients.
This includes CD1a- and CD64-expressing CD14+ monocytes, the
frequencies of which are found to be elevated in the colon of UC
individuals as compared to those in non-UC subjects (Ulrich
Mansmann and our unpublished data), and which were found to be
increased in the human leucocyte cell population isolated from
murine spleens that had been challenged with ethanol. Furthermore,
we could detect the same cells – CD1a-, TSLPR-, and CD80- and/or
CD86-expressing macrophages; and CD1a-, and CD80- and/or
CD86-expressing monocytes – in the murine colon, which were also
present in the colon of UC individuals. In addition, HGF, TARC and
TGFβ1, which have been associated with inflammatory conditions
identified in UC individuals, were also induced in this model.
Treatment of mice with infliximab reflected responses observed in
UC individuals treated with blockers of TNFα, as shown by the
decreased expression of HGF and TARC and by the increased or
unaffected TGFβ1 expression. There are, however, differences when
it comes to the role of CD11b+ macrophages, which play a crucial
role in the acute inflammatory condition in humans as opposed to
inflammation in mice, which seemed to be governed by CD14+
macrophages. In addition, in humans, CD4+ and CD8+ cells are
prominent, whereas inflammatory cell populations were dominated
by CD14+ and CD11b+macrophages in mice. Both effects could be
ascribed to the rather short time after reconstitution. Studies allowing
for longer times of engraftment might shift the balance of cell types.
Although ethanol is considered a dietary factor in UC (Jowett
et al., 2004), by no means can we consider rectal application of 50%
ethanol a naturally occurring trigger of relapses in UC. So far, we
can only speculate how ethanol induced inflammation in our mouse
model. Ethanol or its metabolites might act as toxins to cause
inflammation and exuberant fibrosis, as known from liver diseases.
It might also cause a temporal breach of the epithelial barrier,
allowing the penetration of bacteria to induce inflammation.
Alternatively, ethanol might denature proteins to support an
immunological reaction. As shown in a previous study, oxazolone
is toxic in NSGmice in the absence of PBMCs; ethanol is also toxic,
albeit to a lesser extent than oxazolone. Mice challenged with
oxazolone died spontaneously within 4-12 h post challenge as
opposed to ethanol-challenged mice, which had to be euthanatized
at 48 h post challenge. The toxic effect of ethanol was proven by
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analysis of the macroscopic appearance of the colon, which
displayed constipation and the beginning of necrosis. Histological
analysis revealed edema and an influx of neutrophils, indicating
either influx of bacteria as a result of the barrier breach or wound
healing as a result of epithelial cell damage, or a combination of
both. The fact that NSG mice exhibited lower expression of mucins,
as shown by PAS staining, might give an explanation for the high
susceptibility of NSG mice to ethanol. Mucins provide a protective
shield to impair the contact of bacteria with the mucosa.
Alternatively, the hydrophilic mucus might bind to ethanol or
oxazolone, thus preventing the contact of these toxins with the
mucosa. However, how reconstituted PBMCs can possibly mitigate
the toxic effects of ethanol and, as previously observed, those of
oxazolone remains elusive and has to be elucidated in future studies.
As in previous studies, the immunological background of the donor
influences inflammatory responses (Nolte et al., 2013a,b; Zadeh-
Khorasani et al., 2013). As shown in this study, NSG mice that had
been reconstituted with PBMCs from a healthy donor were affected
by the application of ethanol; however, this resulted most probably
from ethanol intoxication. These mice did not develop diarrhea, and
colon appearance and histology were normal. The increase in
CD64+ CD14+ monocytes in response to challenge that was
observed in mice reconstituted with PBMCs from UC individuals
might provide one explanation. Autoantibody-autoantigen immune
complexes present in the UC background might activate the FcγR1
(CD64) receptor. (Uo et al., 2013). Therefore, we think that this
model might reflect the autoimmune aspect of the disease. Future
studies have to show whether colitis-like symptoms can also be
evoked through exposure to autoantigens, such as proteinase 3
(PR3) detected by pANCAs, which have been identified as a
biological marker of UC (Arias-Loste et al., 2013). This effect has
been previously shown for CD4+ cells monospecific to ovalbumin
(Yoshida et al., 2001). Regardless of the trigger, we feel that this
model can be used to dissect and examine different arms of the
inflammation using inhibitors addressing human target molecules.
In summary, we have shown that this model is partially reflective
of the human disease and can be used to study the efficacy of
therapeutics addressing human target molecules on immune cells.
In combination with immune profiling of UC-affected individuals
and selection of subgroups of individuals for reconstitution of mice,
it might also improve the translatability of preclinical animal studies
to future clinical studies. We feel confident that it might be used to
elucidate the cellular mechanisms that induce and sustain flares of
this disease of subjects in an in vivo model. Finally, it might be a
useful surrogate model for non-human primates, which are used
when high-sequence homology and cross reactivity of human
proteins are necessary.
MATERIALS AND METHODS
Ethical considerations
All donors gave informed written consent, and the study was approved by
the Institutional Review Board (IRB) of the Medical Faculty at the
University of Munich (2015-22).
Animal studies were approved by the ethics committee of the government
of Upper Bavaria, Germany (55.2-1-54-2532-65-11 and 55.2-1-54-2532-
76-15) and performed in compliance with German animal welfare laws.
Isolation of PBMCs and engraftment
Peripheral bloodwas collected from the arm vein ofUC-affected individuals.
Approximately 60 ml of blood in trisodium citrate solution (S-Monovette,
Sarstedt, Nürnberg, Germany) was diluted with Hank’s balanced salt
solution (HBSS; Sigma-Aldrich, Deisenhofen, Germany) in a 1:2 ratio, and
30 ml of the suspension was loaded onto Leukosept tubes (Greiner Bio One,
Frickenhausen, Germany). Cells were separated by centrifugation at 400 g
for 30 min and no acceleration. The interphase fraction containing PBMCs
was extracted and diluted with PBS to a final volume of 40 ml. Cells were
counted and centrifuged at 1400 g for 5 min. The cell pellet was resuspended
in PBS at a concentration of 4×106 cells in 100 µl.
Six- to twelve-week-old NOD-scid IL-2Rγnull mice were engrafted with
100 µl cell solution into the tail vein on day 1.
Study protocol
NOD.cg-PrkdcSCID Il2rgtm1Wjl/Szj mice (abbreviated as NOD-scid
IL-2Rγnull) were obtained from Charles River Laboratories (Sulzfeld,
Germany). Mice were kept under specific pathogen-free conditions in
individually ventilated cages. The facility was controlled according to the
Federation of Laboratory Animal Science Association (FELASA)
guidelines. Following engraftment (day 1), mice were pre-sensitized
through rectal application of 150 µl of 10% ethanol on day 8 using a
1-mm cat catheter (Henry Schein, Hamburg, Germany). The catheter was
lubricated with Xylocain© Gel 2% (AstraZeneca,Wedel). Rectal application
was performed under general anesthesia using 4% isoflurane. Post
application, mice were kept at an angle of 30° to avoid ethanol dripping.
On days 15 and 18, mice were challenged with rectal application of 50%
ethanol following the protocol described for day 8. Mice were killed on day
21. Pitrakinra (10 µg in 0.5% methylcellulose, 0.05% Tween-80) in PBS
(Zadeh-Khorasani et al., 2013) was applied on days 7-9 and 14-21. In these
groups, sterile saline (B. BraunMelsungen AG, Germany) served as control.
Infliximab [6 mg/kg (Remicade©, Janssen, The Netherlands)] was applied
on days 7, 14 and 17. An isotype antibody (human IgG1, kindly provided
by, MorphoSys AG) was used as control. All treatments were applied
intraperitoneally.
Clinical activity score
Assessment of colitis severity was performed daily according to the
following scoring system. The loss of body weight was scored as follows:
0% (0), 0-5% (1), 5-10% (2), 10-15% (3), 15-20% (4). The stool consistency
was scored as follows: formed pellet (0), loose stool or unformed pellet (2),
liquid stools (4). Behavior was scored as follows: normal (0), reduced
activity (1), apathy (4) and ruffled fur (1). Posture was scored as follows:
intermediately hunched posture (1), permanently hunched posture (2). The
scores for each criterion were added daily into a total score with a maximum
of 12 points per day. Animals who suffered from weight loss >20%, rectal
bleeding, rectal prolapse, self-isolation or a severity score >7 were killed
immediately and not taken into count. For statistical analysis, all scores over
all days were added to give the final score.
Isolation of human leucocytes
For isolation of human leucocytes frommurine spleen, spleens were minced
and cells filtrated through a 70-µl cell strainer followed by centrifugation at
1400 g for 5 min and resuspension in FACS buffer. Cell suspensions were
filtrated one more time using a 35-µm cell strainer for further purification
before labeling the cells for flow cytometry analysis.
For isolation of lamina propria mononuclear cells (LPMCs), a protocol of
Weigmann et al. (2007) was modified and used. The washed and minced
colon was predigested twice for 20 min each time in pre-digestion solution
containing 1× HBSS (Thermo Scientific, Darmstadt, Germany), 5 mM
EDTA, 5% FCS, 100 U/ml penicillin-streptomycin (Sigma-Aldrich,
St. Louis, MO) in an orbital shaker with slow rotation (40 g) at 37°C.
Epithelial cells were removed by filtering through a nylon filter. Following
washing with RPMI, the remaining colon pieces were digested twice for
20 min each time in digestion solution containing 1× RPMI (Thermo
Scientific, Darmstadt, Germany), 10% FCS, 1 mg/ml collagenase A
(Sigma-Aldrich, St. Louis, MO), 10 KU/ml DNase I (Sigma-Aldrich,
St. Louis, MO), 100 U/ml penicillin-streptomycin (Sigma-Aldrich,
St. Louis, MO) in an orbital shaker with slow rotation (40 g) at 37°C
(Weigmann et al., 2007).
Isolated LPMCs were collected by centrifugation at 500 g for 10 min and
resuspended for FACS analysis. Cell suspensions were filtrated one more
time using a 35-µm cell strainer for further purification before labeling the
cells for flow cytometry analysis.
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Flow cytometry analysis
Human leucocytes were stained with the antibodies described in Table S4.
Antibodies were diluted 1:200, and 100 μl was used to stain 106 cells.
All antibodies were purchased from BioLegend (San Diego, USA) and
used according to the manufacturer’s instructions. Samples were measured
using a BD FACS Canto II™ instrument and analyzed with FlowJo 10.1-
Software (FlowJo LLC, OR).
Histological analysis
Distal parts of the colon were fixed in 4% formaldehyde for 24 h, followed
by 70% ethanol, and were routinely embedded in paraffin. Samples were cut
into 3-µm sections and stained with hematoxylin and eosin (H&E).
Epithelial erosions were scored as follows: no lesions (1), focal lesions (2),
multifocal lesions (3) and major damage with involvement of basal
membrane (4). Inflammation was scored as follows: infiltration of a few
inflammatory cells into the lamina propria (1); major infiltration of
inflammatory cells into the lamina propria (2); confluent infiltration
of inflammatory cells into the lamina propria (3); and infiltration of
inflammatory cells, including tunica muscularis (4). Fibrosis was scored as
follows: focal fibrosis (1), multifocal fibrosis and crypt atrophy (2). The
presence of edema, hyperemia and crypt abscesses was scored with one
additional point in each case. The scores for each criterion were added into a
total score ranging from 0 to 12. Sections were scored by a certified
veterinarian pathologist in a blinded manner. To evaluate the distribution of
goblet cells, sections were stained with PAS. Images were taken with a Zeiss
AxioVert 40 CFL camera. Figures show representative longitudinal sections
at the original magnification. In Adobe Photoshop CS6, tonal correction was
used in order to enhance contrast within the pictures and was applied equally
to the whole image.
RNA analysis
RNA extraction and cDNA synthesis
Approximately 1-cm (in length) samples from distal parts of the colon were
disrupted and homogenized with the TissueLyser LT (Qiagen, Hilden,
Germany) followed by total RNA extraction according to the manufacturer’s
instruction using RNeasy PlusUniversalMini Kit (Qiagen, Hilden, Germany)
and chloroform (Sigma-Aldrich, St. Louis, MO). No further treatment with
DNase was needed because gDNA Eliminator Solution is included in the kit.
For cDNA synthesis, 5 μg of total RNA was used. Reverse transcription
was performed in a Mastercycler gradient (Eppendorf, Hamburg, Germany)
using QuantiNova Reverse Transcription kit (Qiagen, Hilden, Germany).
Samples were diluted with RNase-free water to obtain a cDNA
concentration between 10 pg and 100 ng as required by the TaqMan Fast
Advanced Master Mix protocol (Thermo Fisher Scientific, Waltham, MA).
RNA and cDNA purity was assessed using a Nanodrop 2000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
Quantitative RT-PCR
According to theTaqManFastAdvancedMasterMix protocol (ThermoFisher
Scientific, Waltham, MA) quantitative RT-PCR was performed using the
Applied Biosystems StepOnePlus RT-PCR system (Thermo Fisher Scientific,
Waltham, MA). Single-tube TaqMan gene expression assays (Thermo Fisher
Scientific, Waltham, MA) included the housekeeping genes GAPDH
(Mm99999915_g1) and GUSB (Mm00446953_m1), as well as TGFβ (Mm
01178820_m1), HGF (Hs04329698_m1), CCL17 (Mm01244826_g1), IFNγ
(HS00989291_m1) and TNFα (HS01113624_g1) (Thermo Fisher Scientific
assay IDs are given in brackets). Analysis was performed using
StepOnePlus™ Software v2.3. For expression analysis, a mean value of
cycle threshold values was calculated for two housekeeping genes. Relative
expression values for the respective analyzed genes were calculated as the
difference between the mean cycle threshold (CT) value of the housekeeping
genes and the respective analyzed gene (delta CT). Relative expression is
depicted as the logarithmic value of the delta CT.
Statistical analysis
Statistical analysis was performed with R software: a language and
environment for statistical computing (R Foundation for Statistical
Computing, Vienna, Austria; https://www.R-project.org/). Variables are
represented with mean, standard deviation, median and interquartile range
(IQR) values. A two-sided Student’s t-test and confidence level=0.95 was
used to compare binary groups, and for more than two groups, ANOVA
followed by Tukey’s honest significant difference (HSD) was conducted.
Sample size calculations were assessed based on a confidence interval of
95% and a power of 80%.
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